Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Landos Biopharma Inc | LABP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 22.93 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 22.93 | 22.93 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.145 - 22.94 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 22.93 | USD |
Landos Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 71.47M | 3.12M | - | 0 | -21.94M | -7.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Landos Biopharma News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LABP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 22.39 | 22.94 | 22.2002 | 22.69 | 25,359 | 0.54 | 2.41% |
| 3 Months | 7.73 | 22.94 | 7.70 | 21.58 | 30,629 | 15.20 | 196.64% |
| 6 Months | 4.28 | 22.94 | 3.21 | 16.38 | 18,009 | 18.65 | 435.75% |
| 1 Year | 3.76 | 22.94 | 3.145 | 11.81 | 13,345 | 19.17 | 509.84% |
| 3 Years | 120.80 | 161.70 | 2.111 | 17.76 | 127,643 | -97.87 | -81.02% |
| 5 Years | 130.00 | 169.89 | 2.111 | 34.16 | 134,018 | -107.07 | -82.36% |
Landos Biopharma Description
| Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. |
